- The ARIEL3 study successfully
achieved its primary endpoint of improved PFS by investigator
review in all three primary efficacy analyses: tumor BRCA-mutant,
HRD-positive and overall intent-to-treat populations
- The ARIEL3 study successfully
achieved the key secondary endpoint of improved PFS by blinded,
independent central review (BICR) in each of the tumor BRCA-mutant,
HRD-positive and overall intent-to-treat populations
- The exploratory PFS endpoints were
achieved by both investigator and independent review in the
HRD-positive and HRD-negative subgroups of patients without a BRCA
mutation
- ARIEL3 patients with residual
disease at study entry who were treated with rucaparib showed
further reduction in tumor burden, including complete
responses
- The safety of rucaparib observed in
ARIEL3 was highly consistent with the U.S. treatment label for
Rubraca®
- The Company plans to submit a
supplemental NDA within the next four months
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced topline
data from the confirmatory phase 3 ARIEL3 trial of rucaparib, which
successfully achieved the primary endpoint of improved
progression-free survival (PFS) by investigator review in each of
the three populations studied. PFS was also improved in the
rucaparib group compared with placebo by blinded independent
central review (BICR), a key secondary endpoint. Based on these
findings, the Company plans to submit a supplemental New Drug
Application (sNDA) within the next four months for a second-line
and later maintenance treatment indication for all women with
platinum-sensitive ovarian cancer who have responded to their most
recent platinum therapy.
“We are very pleased with these positive ARIEL3 topline results
that strongly demonstrate the potential of rucaparib to help women
with platinum-sensitive, advanced ovarian cancer,” said Patrick J.
Mahaffy, President and CEO of Clovis Oncology. “These results
reinforce the potentially foundational role of rucaparib in the
management of advanced ovarian cancer, as demonstrated by both
investigator review and the blinded independent central review.
Most importantly, we are grateful to the patients, caregivers and
investigators who participated in this study. We look forward to
sharing these data in greater detail at a medical meeting later
this year and submitting our sNDA as rapidly as possible, with the
ultimate goal of making rucaparib available to more women battling
ovarian cancer.”
“Based on these encouraging data, it is clear that rucaparib
demonstrates a clinically meaningful impact in delaying disease
recurrence in women in this trial with advanced ovarian cancer,”
said Robert L. Coleman, M.D., professor and vice chair,
clinical research, in the Department of Gynecologic Oncology
and Reproductive Medicine at The University of Texas MD Anderson
Cancer Center in Houston and the U.S. Principal Investigator for
the ARIEL3 study. “The PFS and safety results achieved in this
study are particularly promising, because they suggest women are
able to stay on rucaparib for a prolonged period of time while
gaining benefit. It is also clinically significant that rucaparib
not only sustained the most recent response to platinum, but in
some patients also enhanced that response, including the
elimination of residual tumor.”
“I first dosed a patient with rucaparib over five years ago, and
these robust and exciting data are consistent with my experience,”
said Professor Jonathan Ledermann, Professor of Medical Oncology,
Director, Cancer Research UK and UCL Cancer Trials Centre, UCL
Cancer Institute, and European and ROW Principal Investigator
for the ARIEL3 study. “These results show that rucaparib has the
potential to provide an enduring and important clinical benefit in
women with advanced ovarian cancer, irrespective of their tumor
genetics. This is a very important step forward for women with
advanced ovarian cancer.”
ARIEL3 is a double-blind, placebo-controlled, phase 3 trial of
rucaparib that enrolled 564 women with platinum-sensitive,
high-grade ovarian, fallopian tube, or primary peritoneal cancer.
The primary efficacy analysis evaluated three prospectively defined
molecular sub-groups in a step-down manner: 1) tumor BRCA mutant
(tBRCAmut) patients, inclusive of germline and somatic mutations of
BRCA; 2) HRD-positive patients, including BRCA-mutant patients and
BRCA wild-type with high loss of heterozygosity, or LOH-high
patients; and, finally, 3) the intent-to-treat population, or all
patients treated in ARIEL3.
Following is a table and a summary of the primary efficacy
analyses and selected exploratory PFS endpoints per Response
Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by each of
investigator review, which was the primary analysis of ARIEL3, and
independent review (BICR), a key secondary endpoint of the
study.
Summary of Primary Efficacy Analyses
and Selected Exploratory Endpoints for ARIEL3
ARIEL3
Analysis Population
PFS by Investigator Review
(Primary Endpoint)
PFS by Blinded Independent Central
Review
(Key Secondary Endpoint)
Primary Analyses Hazard
Ratio
Median PFS (months)
Rucaparib vs. Placebo
Hazard Ratio
Median PFS (months)
Rucaparib vs. Placebo
tBRCAmut
(n=196)
0.23; p<0.0001 16.6 vs. 5.4
0.20; p<0.0001 26.8 vs. 5.4
HRD-positive
(n=354)
0.32; p<0.0001 13.6 vs. 5.4
0.34; p<0.0001 22.9 vs. 5.5
Intent-to-Treat
(n=564)
0.36; p<0.0001 10.8 vs. 5.4
0.35; p<0.0001 13.7 vs. 5.4
Exploratory Analyses
BRCAwt / HRD-positive
(n=158)
0.44; p<0.0001 9.7 vs. 5.4
0.55; p=0.0135 11.1 vs. 5.6 BRCAwt /
HRD-negative (n=161) 0.58; p=0.0049
6.7 vs. 5.4
0.47; p=0.0003
8.2 vs. 5.3 PFS: progression-free survival; tBRCAmut:
tumor BRCA mutant; HRD: homologous recombination deficiency;
BRCAwt: BRCA wild type
“Ovarian cancer is the deadliest gynecologic cancer and until
very recently, there were limited treatment options for advanced
disease,” said David Barley, Chief Executive Officer of the
National Ovarian Cancer Coalition. “The potential for targeted
therapies that can meaningfully delay recurrence for a large
percentage of women with this disease is significant, and we are
encouraged by these results from ARIEL3.”
Significant Improvement in PFS in the tBRCAmut Patient
Population
The most robust clinical outcomes were observed among ARIEL3
patients with a germline or somatic BRCA mutation (n=196). By
investigator review, the rucaparib arm successfully achieved
statistical significance over the placebo arm for the primary
endpoint of PFS with a hazard ratio of 0.23 (p<0.0001). The
median PFS for the tBRCAmut patients treated with rucaparib was
16.6 months vs. 5.4 months among those who received placebo.
By independent review (BICR), the rucaparib arm improved PFS
over the placebo arm with a hazard ratio of 0.20 (p<0.0001). The
median PFS for the tBRCAmut patients treated with rucaparib was
26.8 months vs. 5.4 months among those who received placebo.
Results were consistent for the germline BRCA (n=130) and
somatic BRCA (n=56) populations.
Significant Improvement in PFS in the HRD-positive Patient
Population
This population included patients with a germline or somatic
mutation of BRCA, as well as those whose tumors were BRCA wild type
(BRCAwt) but determined to be HRD positive as defined by a
Foundation Medicine assay (n=354). By investigator review, the
rucaparib arm successfully achieved statistical significance over
the placebo arm for the primary endpoint of PFS with a hazard ratio
of 0.32 (p<0.0001). The median PFS for the HRD-positive patients
treated with rucaparib was 13.6 months vs. 5.4 months among those
who received placebo.
By independent review (BICR), the rucaparib arm improved PFS
over the placebo arm with a hazard ratio of 0.34 (p<0.0001). The
median PFS for the HRD-positive patients treated with rucaparib was
22.9 months vs. 5.5 months among those who received placebo.
Significant Improvement in PFS in All Patients
Studied
Rucaparib also showed statistical significance in all 564
patients enrolled in the study. By investigator review, the
rucaparib arm successfully achieved statistical significance over
the placebo arm for the primary endpoint of PFS with a hazard ratio
of 0.36 (p<0.0001). The median PFS for all patients treated with
rucaparib was 10.8 months vs. 5.4 months for those who received
placebo.
By independent review (BICR), the rucaparib arm improved PFS
over the placebo arm with a hazard ratio of 0.35 (p<0.0001). The
median PFS for all patients enrolled in ARIEL3 and treated with
rucaparib was 13.7 months vs. 5.4 months for those who received
placebo.
Exploratory PFS Endpoint Achieved in BRCAwt/HRD-positive
Subgroup
The exploratory PFS endpoint was achieved in the 158 patients
identified as BRCAwt HRD positive. By investigator review, the
rucaparib arm successfully achieved its endpoint over the placebo
arm for the primary endpoint of PFS with a hazard ratio of 0.44
(p<0.0001). The median PFS for these patients treated with
rucaparib was 9.7 months vs. 5.4 months for those who received
placebo.
By independent review (BICR), the rucaparib arm improved PFS
over the placebo arm with a hazard ratio of 0.55 (p=0.014). The
median PFS for these patients treated with rucaparib was 11.1
months vs. 5.6 months for those who received placebo.
Exploratory PFS Endpoint Achieved in BRCAwt/HRD-negative
Subgroup
The exploratory PFS endpoint was achieved in the 161 patients
identified as BRCAwt and HRD negative. By investigator review, the
rucaparib arm successfully achieved its endpoint over the placebo
arm for the primary endpoint of PFS with a hazard ratio of 0.58
(p=0.0049). The median PFS for these patients treated with
rucaparib was 6.7 months vs. 5.4 months for those who received
placebo.
By independent review (BICR), the rucaparib arm improved PFS
over the placebo arm with a hazard ratio of 0.47 (p=.0003). The
median PFS for these patients treated with rucaparib was 8.2 months
vs. 5.3 months for those who received placebo.
Exploratory Endpoint of Response Rate
Enrollment in ARIEL3 included one-third of patients who had
achieved a complete response to their prior platinum-based therapy,
and two-thirds of patients who had achieved a partial response to
their prior platinum-based therapy. Of those with a partial
response, 37% had measurable disease at the time of enrollment and
were therefore evaluable for response. The confirmed overall
response rate by investigator-assessed RECISTv1.1 in the tBRCAmut
group treated with rucaparib was 38% (15/40), of these, 18% (7/40)
were complete responses. This compared with 9% (2/23) in the
placebo group (p=0.0055). No complete responses were seen in the
tBRCAmut placebo group. RECIST responses were also observed in BRCA
wild-type HRD-positive and BRCA wild-type HRD-negative
subgroups.
RECIST responses were not assessed by independent blinded
review.
Summary of ARIEL3 Safety
The most common (≥5%) treatment-emergent grade 3/4 adverse
events (TEAEs) among all patients treated with rucaparib in the
ARIEL3 study were anemia/decreased hemoglobin (19%), ALT/AST
increase (11%), asthenia/fatigue (7%), neutropenia (7%), and
thrombocytopenia (5%).The discontinuation rate for TEAEs was 14%
for rucaparib-treated patients and 2.6% for the placebo arm. The
rate of treatment-emergent myelodysplastic syndrome (MDS)/acute
myeloid leukemia (AML) in the rucaparib arm was <1% (3/372), and
no patients on the placebo arm experienced treatment-emergent
MDS/AML.
Clovis Oncology plans to provide an expanded description of the
ARIEL3 results in a scientific session at a medical meeting later
this year.
Rucaparib and Rubraca® Regulatory Status
In December 2016, Rubraca (rucaparib) tablets became the first
poly ADP-ribose polymerase (PARP) inhibitor approved by the U.S.
Food and Drug Administration (FDA) as monotherapy for treatment of
patients with deleterious BRCA mutation (germline and/or somatic)
associated advanced ovarian cancer who have been treated with two
or more prior chemotherapies. The Company intends to submit a sNDA
for a second line or later maintenance treatment indication in
ovarian cancer based on the ARIEL3 data within the next four
months, and the Company also plans to file a Marketing
Authorization Application (MAA) in Europe for the maintenance
indication.
Conference Call Details
Clovis will hold a conference call to discuss the ARIEL3 results
this morning, June 19, at 8:30am ET. The conference call will be
simultaneously webcast on the Company’s web site at
www.clovisoncology.com, and archived for future review. Dial-in
numbers for the conference call are as follows: U.S. participants
866.489.9022, International participants 678.509.7575, conference
ID: 42436102.
About the ARIEL3 Clinical Trial
The ARIEL3 pivotal study of rucaparib is a confirmatory
randomized, double-blind study comparing the effects of rucaparib
against placebo to evaluate whether rucaparib given as a
maintenance treatment to platinum-sensitive ovarian cancer patients
can extend the period of time for which the disease is controlled
after a complete or partial response to platinum-based
chemotherapy. The study enrolled 564 patients with high-grade
epithelial ovarian, fallopian tube or primary peritoneal cancer. To
be eligible for the study, participants had to have received at
least two prior platinum-based treatment regimens, been sensitive
to the penultimate platinum regimen, and achieved a complete or
partial response to their most recent platinum-based regimen. There
were no genomic selection criteria for this study. Trial
participants were randomized 2:1 to receive 600 milligrams of
rucaparib twice daily (BID) or placebo.
About Rucaparib
Rucaparib is an oral, small molecule inhibitor of PARP1, PARP2
and PARP3 being developed in ovarian cancer as well as several
additional solid tumor indications. The MAA submission in Europe
for an ovarian cancer treatment indication was submitted and
accepted for review during the fourth quarter of 2016. The company
plans to submit data from the completed ARIEL3 trial to the FDA for
an sNDA for a second line and later maintenance treatment
indication. Rucaparib is also being developed in patients with
mutant BRCA tumors and other DNA repair deficiencies beyond BRCA –
commonly referred to as homologous recombination deficiencies, or
HRD. Clovis holds worldwide rights for rucaparib.
About Ovarian Cancer
According to the American Cancer Society, more than 22,400 women
will be diagnosed with ovarian cancer in the U.S. in 2017. There
are often no clearly identifiable initial symptoms, and in an
estimated 80 to 85% of ovarian cancer cases, the cancer has spread
to other parts of the body before a person is diagnosed and can be
treated. Ovarian cancer ranks fifth in cancer deaths and causes
more deaths than any other cancer of the female reproductive
system. One in four women with ovarian cancer have a germline or
somatic BRCA mutation, and new treatment options are needed to
treat unique patient populations.
About Clovis Oncology
Clovis Oncology, Inc. is a biopharmaceutical company
focused on acquiring, developing and commercializing innovative
anti-cancer agents in the U.S., Europe and additional
international markets. Clovis Oncology targets
development programs at specific subsets of cancer populations, and
simultaneously develops, with partners, diagnostic tools intended
to direct a compound in development to the population that is most
likely to benefit from its use. Clovis Oncology is
headquartered in Boulder, Colorado, and has additional offices
in San Francisco,
California, and Cambridge, UK. Please
visit clovisoncology.com for more information.
To the extent that statements contained in this press release
are not descriptions of historical facts regarding Clovis Oncology,
they are forward-looking statements reflecting the current beliefs
and expectations of management made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Examples of forward-looking statements contained in this press
release include, among others, statements regarding our expectation
of timing for submission of the sNDA for rucaparib and to present
the ARIEL3 data set at an upcoming medical meeting. Such
forward-looking statements involve substantial risks and
uncertainties that could cause our future results, performance or
achievements to differ significantly from that expressed or implied
by the forward-looking statements. Such risks and uncertainties
include, among others, the uncertainties inherent in the clinical
development programs for our drug candidates, including the result
of clinical trials, whether future study results will be consistent
with study findings to-date, the corresponding development pathways
of our companion diagnostics, the timing of availability of data
from our clinical trials and the results of our clinical trials,
the initiation, enrollment and timing of our planned clinical
trials, actions by the FDA, the EMA or other regulatory
authorities regarding whether to approve drug applications that may
be filed, as well as their decisions that may affect drug labeling,
pricing and reimbursement, and other matters that could affect the
availability or commercial potential of our drug candidates or
companion diagnostics. Clovis Oncology does not undertake to
update or revise any forward-looking statements. A further
description of risks and uncertainties can be found in Clovis
Oncology’s filings with the Securities and Exchange Commission,
including its Annual Report on Form 10-K and its reports on Form
10-Q and Form 8-K.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170619005376/en/
Clovis Investor Contacts:Anna Sussman,
303.625.5022asussman@clovisoncology.comorBreanna Burkart,
303.625.5023bburkart@clovisoncology.comorClovis Media
Contacts:Lisa Guiterman,
301.217.9353clovismedia@sambrown.comorChristy Curran,
615.414.8668clovismedia@sambrown.com
Clovis Oncology (NASDAQ:CLVS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Clovis Oncology (NASDAQ:CLVS)
Historical Stock Chart
From Apr 2023 to Apr 2024